Article
Medicine, General & Internal
Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Y. Cheah, John M. Pagel, Jennifer A. Woyach, Bita Fakhri, Toby A. Eyre, Nicole Lamanna, Manish R. Patel, Alvaro Alencar, Ewa Lech-Maranda, William G. Wierda, Catherine C. Coombs, James N. Gerson, Paolo Ghia, Steven Le Gouill, David John Lewis, Suchitra Sundaram, Jonathon B. Cohen, Ian W. Flinn, Constantine S. Tam, Minal A. Barve, Bryone Kuss, Justin Taylor, Omar Abdel-Wahab, Stephen J. Schuster, M. Lia Palomba, Katharine L. Lewis, Lindsey E. Roeker, Matthew S. Davids, Xuan Ni Tan, Timothy S. Fenske, Johan Wallin, Donald E. Tsai, Nora C. Ku, Edward Zhu, Jessica Chen, Ming Yin, Binoj Nair, Kevin Ebata, Narasimha Marella, Jennifer R. Brown, Michael Wang
Summary: The study evaluated the safety and efficacy of the highly selective, reversible BTK inhibitor pirtobrutinib in patients with various B-cell malignancies. Results showed that pirtobrutinib demonstrated good efficacy in patients previously treated with covalent BTK inhibitors and did not reach the maximum tolerated dose.
Article
Oncology
Mark A. Dawson, Gautam Borthakur, Brian J. P. Huntly, Anastasios Karadimitris, Adrian Alegre, Aristeidis Chaidos, Dan T. Vogl, Daniel A. Pollyea, Faith E. Davies, Gareth J. Morgan, Jacob L. Glass, Manali Kamdar, Maria -Victoria Mateos, Natalia Tovar, Paul Yeh, Regina Garcia Delgado, Faisal Basheer, Ludovica Marando, Paolo Gallipoli, Anastasia Wyce, Anu Shilpa Krishnatry, Olena Barbash, Evi Bakirtzi, Geraldine Ferron-Brady, Natalie O. Karpinich, Michael T. McCabe, Shawn W. Foley, Thierry Horner, Arindam Dhar, Brandon E. Kremer, Michael Dickinson
Summary: Molibresib, a selective inhibitor of BET proteins, was evaluated as a monotherapy for hematological malignancies. The study consisted of dose escalation to determine the recommended dose and dose expansion to assess safety and efficacy in relapsed/refractory MDS and CTCL patients. Results showed limited antitumor activity and significant toxicities, suggesting the need for combination regimens with molibresib.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Stephen M. Ansell, Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas, Mark D. Minden, Diego Villa, Mary-Elizabeth M. Percival, Anjali S. Advani, James M. Foran, Steven M. Horwitz, Matthew G. Mei, Jasmine Zain, Kerry J. Savage, Christiane Querfeld, Oleg E. Akilov, Lisa D. S. Johnson, Tina Catalano, Penka S. Petrova, Robert A. Uger, Eric L. Sievers, Anca Milea, Kathleen Roberge, Yaping Shou, Owen A. O'Connor
Summary: The study evaluated the safety and activity of TTI-621 in relapsed/refractory hematologic malignancies, indicating that TTI-621 demonstrated certain therapeutic effects and good tolerability overall in patients.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Beatrice Casadei, Lisa Argnani, Alessandro Broccoli, Caterina Patti, Piero Maria Stefani, Antonio Cuneo, Gloria Margiotta Casaluci, Carlo Visco, Guido Gini, Fabrizio Pane, Francesco D'Alo, Debora Luzi, Maria Cantonetti, Samantha Pozzi, Gerardo Musuraca, Chiara Rosignoli, Annalisa Arcari, Sofya Kovalchuk, Monica Tani, Maria Chiara Tisi, Mario Petrini, Vittorio Stefoni, Pier Luigi Zinzani
Summary: Idelalisib, as a first-in-class phosphatidylinositol 3-kinase inhibitor, has been approved for the treatment of relapsed/refractory follicular lymphoma patients, showing high antitumor activity with an acceptable safety profile. A 6-year follow-up study confirmed its efficacy and manageable safety in real-life settings for patients with unfavorable prognostic characteristics.
Article
Oncology
Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Simkovic, Jiri Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A. Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak
Summary: The study compared the efficacy and safety of zanubrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. The results showed that zanubrutinib had better outcomes in terms of efficacy, atrial fibrillation rate, and cardiac safety compared to ibrutinib.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Immunology
Hua Li, Xiaofan Li, Yiling Chen, Duihong Li, Xianling Chen, Zhijuan Zhu, Yiting Wang, Jiafu Huang, Ping Chen, Yuanzhong Chen, Nainong Li
Summary: The study showed that sequential Haplo-cord HSCT with ATG/PTCY may improve survival outcomes for patients with relapsed/refractory hematologic malignancies, showing better overall survival and disease-free survival compared to single cord transplantation.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Sima Jeha, Kristine R. Crews, Deqing Pei, Melissa Peyton, John C. Panetta, Raul C. Ribeiro, Xujie Zhao, Patrick Campbell, Monika L. Metzger, Jun J. Yang, Cheng Cheng, Ching-Hon Pui, Deepa Bhojwani
Summary: The study found that bendamustine in combination with clofarabine and etoposide is well tolerated and effective in treating relapsed or refractory hematologic malignancies in children and adolescents.
Article
Oncology
Sikander Ailawadhi, Zi Chen, Bo Huang, Aneel Paulus, Mary C. Collins, Lei (Tommy) Fu, Mingyu Li, Mohammad Ahmad, Lichuang Men, Hengbang Wang, Matthew S. Davids, Eric Liang, Divya J. Mekala, Zhicong He, Masa Lasica, Costas K. Yannakou, Ricardo Parrondo, Laura Glass, Dajun Yang, Asher Chanan-Khan, Yifan Zhai
Summary: This global phase I trial aimed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of lisaftoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL) and other hematologic malignancies (HMs). The results demonstrated that lisaftoclax was well tolerated, had a short plasma residence, and induced rapid clinical responses in R/R CLL/SLL patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Medicine, General & Internal
J. R. Brown, B. Eichhorst, P. Hillmen, W. Jurczak, M. Kazmierczak, N. Lamanna, S. M. O'Brien, C. S. Tam, L. Qiu, K. Zhou, M. Simkovic, J. Mayer, A. Gillespie-Twardy, A. Ferrajoli, P. S. Ganly, R. Weinkove, S. Grosicki, A. Mital, T. Robak, A. Osterborg, H. A. Yimer, T. Salmi, M. -D. -Y. Wang, L. Fu, J. Li, K. Wu, A. Cohen, M. Shadman
Summary: In a multinational phase 3 trial, zanubrutinib was found to be superior to ibrutinib in treating relapsed or refractory CLL or SLL, with better efficacy and fewer side effects.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Mick J. M. van Eijs, Lotte E. van der Wagen, Rogier Mous, Roos J. Leguit, Lisette van de Corput, Anne S. R. van Lindert, Britt B. M. Suelmann, Anna M. Kamphuis, Stefan Nierkens, Karijn P. M. Suijkerbuijk
Summary: Immune checkpoint inhibition (ICI) has shown promise in treating advanced malignancies, but there have been reported cases of hematological neoplasia following ICI for solid tumors. In this study, we present five cases of myeloid malignancies (chronic myeloid leukemia, acute myeloid leukemia, myelodysplastic syndrome, chronic eosinophilic leukemia) in patients treated with anti-PD-1-based therapy. Molecular analyses were performed to identify baseline variants in myeloid genes, and we discuss the potential mechanisms underlying the progression to myeloid malignancies.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Vikram J. Premkumar, Suzanne Lentzsch, Samuel Pan, Divaya Bhutani, Joshua Richter, Sundar Jagannath, Michaela Liedtke, Arnaud Jaccard, Ashutosh D. Wechalekar, Raymond Comenzo, Vaishali Sanchorawala, Bruno Royer, Michael Rosenzweig, Jason Valent, Stefan Schonland, Rafael Fonseca, Sandy Wong, Prashant Kapoor
Summary: Venetoclax demonstrates efficacy in relapsed/refractory t(11;14) multiple myeloma and shows potential for treatment in light-chain amyloidosis. Patients with t(11;14) exhibit better response to venetoclax and longer progression-free survival (PFS) time.
BLOOD CANCER JOURNAL
(2021)
Article
Biochemistry & Molecular Biology
Andras Heczey, Xin Xu, Amy N. Courtney, Gengwen Tian, Gabriel A. Barragan, Linjie Guo, Claudia Martinez Amador, Nisha Ghatwai, Purva Rathi, Michael S. Wood, Yanchuan Li, Chunchao Zhang, Thorsten Demberg, Erica J. Di Pierro, Andrew C. Sher, Huimin Zhang, Birju Mehta, Sachin G. Thakkar, Bambi Grilley, Tao Wang, Brian D. Weiss, Antonino Montalbano, Meena Subramaniam, Chenling Xu, Chirag Sachar, Daniel K. Wells, Gianpietro Dotti, Leonid S. Metelitsa
Summary: This study presented updated interim results on the evaluation of GD2-specific CAR-expressing NKT cells co-expressing IL15 in children with NB. The results showed that GD2-CAR.15 NKT cells had anti-tumor activity, which could be enhanced by targeting BTG1.
Article
Oncology
Nathan H. Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopinska-Posluszny, Chan Y. Cheah, Tycel Phillips, Ewa Lech-Maranda, Bruce D. Cheson, Paolo F. Caimi, Sebastian Grosicki, Lori A. Leslie, Julio C. Chavez, Gustavo Fonseca, Sunil Babu, Daniel J. Hodson, Spencer H. Shao, John M. Burke, Jeff P. Sharman, Jennie Y. Law, John M. Pagel, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Michael S. Weiss, Pier Luigi Zinzani
Summary: Umbralisib demonstrated meaningful clinical activity in heavily pretreated patients with iNHL. The safety profile was manageable, with a relatively low incidence of immune-mediated toxicities and adverse event-related discontinuations.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Sham Mailankody, Jeffrey V. Matous, Saurabh Chhabra, Michaela Liedtke, Surbhi Sidana, Olalekan O. Oluwole, Shahbaz Malik, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, Myo Htut, Erin E. Karski, Wade Lovelace, Myles Dillon, Eric Butz, Wendy Ying, Arun Balakumaran, Shaji K. Kumar
Summary: In an interim phase 1 trial analysis, escalating doses of off-the-shelf allogeneic anti-BCMA CAR T cells, in combination with an anti-CD52 antibody-containing lymphodepletion regimen, were shown to be feasible and safe for the treatment of relapsed or refractory multiple myeloma.
Article
Hematology
Eleonora Calabretta, Martina di Trani, Francesco Corrado, Martina Sollini, Vanessa Cristaldi, Fabrizio Marino, Lodovico Terzi di Bergamo, Alessio Bruscaggin, Maria Cristina Pirosa, Stefania Bramanti, Arturo Chiti, Davide Rossi, Carmelo Carlo-Stella
Summary: This study aims to evaluate the predictive and prognostic value of ctDNA in relapsed/refractory Hodgkin lymphoma (cHL). The findings suggest that ctDNA genotyping can reflect gene mutations and pathways in cHL, while baseline ctDNA quantification and serial monitoring can serve as prognostic indicators. Additionally, integrating ctDNA quantification with iPET evaluation helps to identify patients at high risk of treatment failure.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
